Lung cancer incidence following negative biopsy

Principal Investigator

Name
Paul Pinsky

Institution
NCI

Position Title
Chief, EDRG

Email
pp4f@nih.gov

About this CDAS Project

Study
NLST (Learn more about this study)

Project ID
NLST-1498

Initial CDAS Request Approval
Mar 16, 2026

Title
Lung cancer incidence following negative biopsy

Summary
Lung cancer has the second highest incidence of any cancer and represents the leading cause of cancer death in both women and men in the United States. Most lung cancers are diagnosed in late stage when 5 year survival is <10%.1,2 Whereas many positive findings on Lung-RADS lesions are recommended to undergo radiographic surveillance, Lung-RADS category 4 findings lesions may require additional diagnostic imaging or tissue sampling. Tissue sampling may be performed with bronchoscopic, trans-cutaneous, or surgical biopsy/resection.
In this project, we examine the incidence of lung cancer following negative biopsy after a positive LDCT screen. We also examine the location of the biopsy in relation to that of the eventual lung tumor.

Aims

Compare lung cancer incidence in those with negative biopsy by biopsy type

Look at risk factors for lung cancer incidence in a multivariate model.

Compare incidence in those with negative biopsy to that of a control group

Compare biopsy lobe location to tumor lobe location among those with eventual lung cancer.

Compare lung cancer incidence in those with negative biopsy by biopsy type

Look at risk factors for lung cancer incidence in a multivariate model.

Compare incidence in those with negative biopsy to that of a control group

Compare biopsy lobe location to tumor lobe location among those with eventual lung cancer.

Collaborators

Elyse Leevan NCI
Paul Pinsky NCI